Skip to main content

Advertisement

Table 2 Subgroup Analyses of the Associations between LMR and overall survival

From: Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis

Variables No. of studies Test of association Test of heterogeneity
HR 95% CI P value I2 (%) P value
Total 35 0.578 0.522–0.641 < 0.001 70.10 < 0.001
Publication year
 ≤ 2016 18 0.572 0.497–0.660 < 0.001 67.20 < 0.001
 > 2016 17 0.583 0.499–0.681 < 0.001 72.60 < 0.001
Initial inclusion period
 ≤ 2006 19 0.554 0.480–0.640 < 0.001 72.90 < 0.001
 > 2006 16 0.604 0.516–0.707 < 0.001 68.20 < 0.001
Research region
 Asia 28 0.584 0.520–0.656 < 0.001 74.90 < 0.001
 Europe 5 0.553 0.446–0.685 < 0.001 0.00 0.712
 America and others 2 0.584 0.459–0.744 < 0.001 0.00 0.596
Number of cases
 < 200 19 0.632 0.547–0.730 < 0.001 63.20 < 0.001
 > 200 16 0.549 0.497–0.606 < 0.001 41.30 0.043
Median age (years)
 ≤ 60 13 0.585 0.496–0.691 < 0.001 69.20 < 0.001
 > 60 13 0.575 0.488–0.679 < 0.001 75.70 < 0.001
 NR 9 0.557 0.427–0.727 < 0.001 62.60 0.006
Tumor types
 Breast cancer 1 0.47 0.171–1.295 0.144
 Cervical carcinoma 1 0.337 0.164–0.691 0.003
 Colon cancer and rectal cancer 13 0.579 0.516–0.650 < 0.001 0.00 0.496
 Ovarian cancer 1 0.615 0.527-0.718 < 0.001
 Esophageal cancer 1 0.495 0.315– 0.778 0.002
 Gastric cancer 2 0.664 0.523–0.843 0.001 0.00 0.622
 Head and neck cancer 1 0.28 0.168–0.466 < 0.001
 Hepatocellular carcinoma 1 0.73 0.399–1.336 0.308
 Lung cancer 5 0.594 0.435–0.811 0.001 85.50 < 0.001
 Nasopharyngeal carcinoma 2 0.479 0.406–0.566 < 0.001 0.00 0.379
 Pancreatic cancer 5 0.588 0.407–0.851 0.005 67.90 0.014
 Renal cancer 2 0.827 0.755–0.906 < 0.001 0.00 0.7
LMR cutoff
 < 3.0 9 0.508 0.444–0.582 < 0.001 16.00 0.3
 ≥ 3.0 26 0.612 0.546–0.686 < 0.001 69.80 < 0.001
Therapeutic strategies
 Chemotherapy 10 0.592 0.518–0.676 < 0.001 31.90 0.153
 Molecular targeted 2 0.622 0.304–1.271 0.193 93.00 < 0.001
 Surgery 10 0.683 0.579–0.807 < 0.001 54.30 0.02
 Combined therapy 11 0.507 0.442–0.582 < 0.001 37.90 0.097
 Others 2 0.563 0.400–0.794 0.001 0.00 0.577
Follow-up period (months)
 ≤ 33 13 0.545 0.454–0.653 < 0.001 67.80 < 0.001
 > 33 9 0.594 0.515–0.685 < 0.001 15.60 0.303
 NR 13 0.606 0.504–0.729 < 0.001 81.10 < 0.001
Quality score
 < 7 3 0.753 0.592–0.958 0.021 83.20 0.003
 ≥ 7 32 0.558 0.504–0.619 < 0.001 58.30 < 0.001
Analysis of hazard ratio
 Multivariate 32 0.562 0.503–0.628 < 0.001 68.70 < 0.001
 Univariate 3 0.755 0.643–0.887 0.001 23.30 0.272
  1. CI confidence interval, HR hazard ratio, No. number, LMR lymphocyte-to-monocyte ratio